Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNIEHV)

Drug Name
APC-300 Drug Info
Synonyms CPC-300
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Investigative [1]
Cross-matching ID
TTD Drug ID
DMNIEHV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting GTPase NRas (NRAS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salirasib DMRSU4X Lung cancer 2C25.0 Phase 2 [2]
Mutant ras vaccine DMM6KZR Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
GI-4000 DMTY4PG Colorectal cancer 2B91.Z Phase 2 [4]
Reovirus DMQ73AY Head and neck cancer 2D42 Phase 2 [5]
Perillyl alcohol DMFWC3O Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [1]
KA-10X DM4GSHY Solid tumour/cancer 2A00-2F9Z Investigative [1]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GTPase NRas (NRAS) TTW2R9X RASN_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823).
2 The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467-89.
3 The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014 Feb 24;12:55.
4 Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer. 2014 Nov;15(6):405-10.
5 Reovirus (Reolysin) as a potential therapy for malignant peripheral nerve sheath tumors.